Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensifentrine in COPD
NCT05270525Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- May 2022
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ensifentrine in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Merck & Co. Primary endpoint: Absolute Change From Baseline in Sputum Neutrophil Cell Numbers at 8 weeks. Started May 2022; status: active, not recruiting.
02
Drugs
ensifentrine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05270525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05270525.